EFMH
PTGX icon

E Fund Management (HK)’s Protagonist Therapeutics PTGX Stock Holding History

E Fund Management (HK)’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.9K Buy
211
+55
+35% +$5.75K 0.01% 260
2026
Q1 		$16.4K Buy
+156
New +$13.8K 0.01% 228

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

E Fund Management (HK)'s PTGX Position: Q2 2026 in Review

E Fund Management (HK) increased its Protagonist Therapeutics (PTGX) stake by 35% in Q2 2026, buying an estimated $5.75K and bringing the position to 211 shares worth $25.9K. The position accounts for 0.01% of the portfolio, ranked #260.

E Fund Management (HK) first reported a position in PTGX in Q1 2026 and has held it in 2 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • E Fund Management (HK) held 211 shares of Protagonist Therapeutics worth $25.9K as of Q2 2026.
  • E Fund Management (HK) bought 55 Protagonist Therapeutics shares in Q2 2026, an estimated $5.75K.
  • Protagonist Therapeutics made up 0.01% of E Fund Management (HK)'s portfolio in Q2 2026, its #260 holding.
  • E Fund Management (HK) first reported a position in Protagonist Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on E Fund Management (HK)'s 13F filing for Q2 2026, filed 22 Jul 2026.